Severe Asthma (SA) is characterized by the difficulty of controlling exacerbations and asthma symptoms despite optimized therapy. This type of asthma affects a minor subset of asthma patients, but represents a relevant proportion of asthma healthcare costs. Therefore, this study focused on estimating the number of patients aged >12 years old treated by specialists (pneumologists and allergists) in Portugal and the share under biologic treatment. A physician’s primary market research study was conducted through computer assisted web interviewing. Among a sample of 62 physicians, a total of 50 biologic prescribers’ physicians completed the survey (30 pneumologists and 20 allergists). Results were extrapolated based on physicians’ reported number of total SA patients and under biologics within the past 12 months. It is estimated that approximately 3.6% of asthma patients aged above 12 years old (19,733 patients) were treated for SA by pneumologists and allergists in 2018. Among these, approximately 67% presented an allergic pattern of asthma. Regarding its phenotypes, 26% of SA patients presented high IgE levels (> 30UI/mL), 30% revealed high eosinophil levels (> 150/μl) and 35% showed a mixed profile with both biomarkers augmented. It was estimated that 10% of patients did not have increased levels of these biomarkers. Among SA patients, it was predicted that approximately 4.9% received biologic therapy during past year (984 patients). Additionally, 86% of physicians mentioned there was a growth in the number of SA patients in the past 3 years. This study provides an estimate of 19,733 SA patients seen by a specialist in Portugal in the past year. Iit was projected that approximately 984 SA patients (4.9%) received a biologic for asthma treatment in the past 12 months. Furthermore, physicians recognized an increase SA diagnosis, which reveals an increased awareness of SA.